Sign in
Taking people in United StatesPhase 2

Stem cell transplant from a relative for severe aplastic anemia, MDS, or PNH

Tests stem cells from a relative plus chemotherapy in people with serious blood disorders.

Key facts

Who runs it
National Heart, Lung, and Blood Institute (NHLBI)
Where
Bethesda, United StatesSee the site
Trial code
Registry title
Haplo-identical Transplantation for Severe Aplastic Anemia, Hypo-plastic MDS and PNH Using Peripheral Blood Stem Cells and Post-transplant Cyclophosphamide for GVHD Prophylaxis
Status
Recruiting
Phase
Phase 2
People taking part
56 people, planned
Started
19 Feb 2019
Expected to end
1 Jun 2028
Type of study
Interventional
Treatments tested
  • Cyclophosphamide
  • Peripheral Blood Stem Cells
Record updated
2 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people aged 4-60 with severe aplastic anemia, hypoplastic MDS or PNH who need a stem cell transplant from a half-matched family donor. Donors aged 4-75 also take part.

Age
Recipients 4-60 years; related donors 4-75 years.
Sex
All sexes can join.
Disease stage
Severe aplastic anemia with bone marrow cellularity <30% and transfusion dependence and/or low neutrophils; or aplastic anemia that turned into MDS (IPSS INT-1 or greater, <5% myeloblasts, <30% cellularity); or PNH that is life-threatening or causes transfusion dependence or recurrent severe hemolytic crises.
Earlier treatment
Intolerance of or no response to immunosuppressive therapy (ATG and cyclosporine, or cyclosporine with eltrombopag). PNH must not respond to eculizumab/ravulizumab, or the person has no access to it.
Biomarker or test result
At least one haploidentical related donor (>= 5/10 HLA match) and a backup donor or cord blood unit. No HLA antibodies against the donor's mismatched HLA alleles.

Main reasons for not taking part

  • A fully HLA-matched (12/12) donor is available, or the person is a candidate for a 12/12 matched unrelated transplant
  • ECOG performance status of 2 or more
  • Current pregnancy, or unwillingness to prevent pregnancy for one year
  • HIV positive, or Fanconi's anemia
  • Serious heart, lung, liver or kidney problems, or an active infection not responding to treatment

The registry criteria, word for word

Show all 22 criteriaShow less

Who can take part

  • Donor deemed suitable and eligible, and willing to donate, per clinical evaluations who are additionally willing to donate blood for research. Donors will be evaluated in accordance with existing Standard NIH Policies and Procedures for determination of eligibility and suitability for clinical donation. Note that participation in this study is offered to all donors, but is not required for a donor to make a stem cell donation, so it is possible that not all donors will enroll onto this study

Who cannot take part

  • The patient is deemed to be a candidate for a 12/12 HLA matched unrelated stem cell transplant (availability of a donor and resources required for such a transplant)
  • Major anticipated illness or organ failure incompatible with survival from transplant
  • HIV positive
  • Presence of an active infection not adequately responding to appropriate therapy
  • History of a malignant disease liable to relapse or progress within 5 years
  • Left ventricular ejection fraction <40% (evaluated by ECHO)
  • Transaminases > 5x upper limit of normal
  • Direct bilirubin >3 mg/dl
  • Creatinine clearance < 50 cc/min/BSAm\^2 by 24-hour urine collection adjusted by body surface area
  • Serum creatinine > 2.5 mg/dl
  • Availability of an HLA identical (12/12) matched related or unrelated donor who is available within optimal timeline and suitable considering graft source and established donor selection factors (e.g. age, sex, viral exposure, ABO compatibility, pregnancy status, etc) per PI discretion
  • Diffusion capacity of carbon monoxide (DLCO) <40% using DLCO corrected for Hgb or lung volumes (patients under the age of 10 may be excluded from this criterion if they have difficulty performing the test correctly and thus are unable to have their DLCO assessed)
  • ECOG performance status of 2 or more
  • Current pregnancy, or unwillingness to take oral contraceptives or use a barrier method of birth control or practice abstinence to refrain from pregnancy, if of childbearing potential for one year
  • Diagnosis of Fanconi s anemia (by chromosome breakage study)
  • None

Other criteria

  • INCLUSION CRITERIA - RECIPIENT:
  • Diagnosed with severe aplastic anemia with bone marrow cellularity <30% (excluding lymphocytes) associated with RBC or platelet transfusion dependence and/or neutropenia (absolute neutrophil count less than or equal to 1000 cells/ microL or for patients receiving granulocyte transfusions, absolute neutrophil count less than or equal to 1000 cells/microL before beginning granulocyte transfusions); OR; --History of severe aplastic anemia transformed to MDS. that meet the following criteria: a) International Prognostic Scoring System (IPSS) risk category of INT-1 or greater, b) <5% myeloblasts and <30% of cellularity in the bone marrow on screening morphologic analysis; OR
  • PNH that is either refractory to treatment with eculizumab/ravulizumab or occurs in patients who don t have access to treatment with eculizumab associated with either a) life- threatening thrombosis and/or b) cytopenia associated with transfusion dependence and/or c) recurrent and debilitating hemolytic crisis; Subjects with severe aplastic anemia, hypoplastic MDS or PNH with associated bone marrow failure syndromes who have intolerance of or failure to respond to immunosuppressive therapy. This also includes patients who have failed immunosuppressive therapy with ATG and cyclosporine or therapy with cyclosporine combined with eltrombopag in those who are intolerant of or do not have access to treatment with ATG; Availability of at least one HLA- haploidentical related donor (i.e. >= 5/10 HLA match: HLA-A, B, C, DR, and DQ loci) to serve as a stem cell donor for the allogeneic transplant; Availability of a backup stem cell source in the event of graft rejection:
  • at least one additional haploidentical related alternative donor (i.e. HLA- haploidentical related donor (i.e. >= 5/10 HLA match: HLA-A, B, C, DR, and DQ loci) or >= 9/10 HLA matched unrelated donor who is available to serve as a stem cell donor for a salvage allogeneic transplant in the event that the haplo-transplant has been rejected
  • umbilical cord blood unit/s that can be used for a salvage cord blood transplant in the event that the haplo-transplant has been rejected; The patient does not have any HLA antibodies detectable against any of the mismatched HLA alleles expressed by the haplo-donor; Ages 4-60 years inclusive; Ability to comprehend the investigational nature of the study and provide informed consent. The procedure will be explained to subjects aged 4-17 years with formal consent being obtained from parents or legal guardian

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 4 and 75 years old?

Where in United States

  • National Institutes of Health Clinical CenterBethesda, United StatesContact: Jennifer A FarrenTaking people

About the trial

What the trial wants to find out

Background:

Read full original descriptionShow less

Severe aplastic anemia (SAA), and myelodysplastic syndrome (MDS), and paroxysmal nocturnal hemoglobinuria

(PNH) cause serious blood problems. Stem cell transplants using bone marrow or blood plus chemotherapy can help. Researchers want to see if using peripheral blood stem cells (PBSCs) rather than bone marrow cells works too. PBSCs are easier to collect and have more cells that help transplants.

Objectives:

To see how safely and effectively SAA, MDS and PNH are treated using peripheral blood hematopoietic stem cells from a family member plus chemotherapy.

Eligibility:

Recipients ages 4-60 with SAA, MDS or PNH and their relative donors ages 4-75

Design:

Recipients will have:

* Blood, urine, heart, and lung tests * Scans * Bone marrow sample

Recipients will need a caregiver for several months. They may make fertility plans and a power of attorney.

Donors will have blood and tissue tests, then injections to boost stem cells for 5-7 days.

Donors will have blood collected from a tube in an arm or leg vein. A machine will separate stem cells and maybe white blood cells. The rest of the blood will be returned into the other arm or leg.

In the hospital for about 1 month, recipients will have:

* Central line inserted in the neck or chest * Medicines for side effects * Chemotherapy over 8 days and radiation 1 time * Stem cell transplant over 4 hours

Up to 6 months after transplant, recipients will stay near NIH for weekly physical exams and blood tests.

At day 180, recipients will go home. They will have tests at their doctor s office and NIH several times over 5 years.

The group in the trial

  • Treatment ArmTreatment being tested

    G-CSF mobilized peripheral stem cells and post haplo-identical transplantation cyclophosphamide

    Treatment: Cyclophosphamide and Peripheral Blood Stem Cells

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Haplo-identical Transplantation for Severe Aplastic Anemia, Hypo-plastic MDS and PNH Using Peripheral Blood Stem Cells and Post-transplant Cyclophosphamide for GVHD Prophylaxis
Plain-language title
Stem cell transplant from a relative for severe aplastic anemia, MDS, or PNHGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT03520647, who can take part
Record updated
2 November 2026